Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
Gothenburg, SE
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.43% | -2.05% | -18.16% | -32.39% | -47.06% | -38.11% | -83.54% | -87.33% | -96.75% | -89.27% | -89.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-39.3% Q1'26: +802.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-2.5% Q1'26: +116.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-111.9% Q1'26: -72.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-160.7% Q1'26: +24.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +237.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+29.2% Q1'26: +57.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.34× Q1'26: 0.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
109.0K
est: 4.0K (+2,625.0%)
|
18.0K
est: 40.0K (-55.0%)
|
207.78M
est: 205.62M (+1.1%)
|
61.14M
est: 53.05M (+15.2%)
|
5.68M
est: 41.59M (-86.3%)
|
94.63M
est: 132.00M (-28.3%)
|
57.46M
est: 56.30M (+2.1%)
|
96.90M
96.90M – 96.90M
+72.1% YoY
|
142.50M
142.50M – 142.50M
+47.1% YoY
|
| EBITDA |
-53.87M
est: -2.8K (-1,951,711.6%)
|
-72.57M
est: -27.6K (-262,759.5%)
|
55.79M
est: -141.91M (+139.3%)
|
-109.13M
est: -36.61M (-198.1%)
|
-173.32M
est: -28.70M (-503.9%)
|
-68.07M
est: -91.10M (+25.3%)
|
-88.03M
est: -38.86M (-126.6%)
|
-66.88M
-66.88M – -66.88M
-72.1% YoY
|
-98.35M
-98.35M – -98.35M
-47.1% YoY
|
| EBIT |
-54.22M
est: -2.8K (-1,928,715.4%)
|
-74.10M
est: -28.1K (-263,438.1%)
|
52.58M
est: -144.54M (+136.4%)
|
-113.11M
est: -37.29M (-203.3%)
|
-177.64M
est: -29.23M (-507.7%)
|
-72.65M
est: -92.79M (+21.7%)
|
-92.35M
est: -39.58M (-133.3%)
|
-68.12M
-68.12M – -68.12M
-72.1% YoY
|
-100.17M
-100.17M – -100.17M
-47.1% YoY
|
| Net Income |
-56.23M
est: -78.43M (+28.3%)
|
-74.10M
est: -28.63M (-158.9%)
|
51.78M
est: 92.55M (-44.1%)
|
-114.20M
est: -146.42M (+22.0%)
|
-177.84M
est: -154.30M (-15.3%)
|
-83.13M
est: -103.34M (+19.6%)
|
-110.01M
est: -177.11M (+37.9%)
|
-175.85M
-175.85M – -175.85M
+0.7% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
42.60M
est: 183.1K (+23,170.9%)
|
54.27M
est: 1.83M (+2,864.4%)
|
81.74M
est: 9.41B (-99.1%)
|
125.91M
est: 2.43B (-94.8%)
|
53.08M
est: 64.84M (-18.1%)
|
-163.67M
est: 205.81M (-179.5%)
|
-130.79M
est: 87.78M (-249.0%)
|
151.08M
151.08M – 151.08M
+72.1% YoY
|
222.18M
222.18M – 222.18M
+47.1% YoY
|
| EPS |
-1.64
est: -1.51 (-8.5%)
|
-1.90
est: -0.55 (-244.3%)
|
1.00
est: 1.78 (-44.0%)
|
-2.20
est: -2.82 (+22.1%)
|
-3.43
est: -2.30 (-48.9%)
|
-1.60
est: -1.27 (-25.5%)
|
-1.64
est: -2.64 (+38.0%)
|
-2.62
-2.62 – -2.62
+0.7% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicholas Waters | Executive Vice President and Head of R&D | 2M | — |
| Kristina Torfgard | Chief Executive Officer | 1M | — |
| Joakim Tedroff | Chief Medical Officer | 5.0K | — |
| Cecilia Tivert Stenberg | Head of Finance & Human Resource and Director of Accounting & Human Resources | — | female |
| Gustaf Albèrt | Chief Financial Officer | — | male |
| Clas Sonesson | Chief Scientific Officer | — | — |
| Peder Svensson | Chief Information Officer and Director of Computational Chemistry & Biology | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IRLAB-A.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
